1L	first line
1LM	first-line maintenance
2L	second line
3L	third line
ADC	antibody–drug conjugates
CCQP	Cancer Care Quality Program
CI	confidence interval
DDMVAC	dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin
DMF	Death Master File
ECOG PS	Eastern Cooperative Oncology Group performance score
ER	emergency room
EV	enfortumab vedotin
FDA	Food and Drug Administration
HCRU	healthcare resource utilization
HIRD®	Healthcare Integrated Research Database
IO	immuno-oncology
IQR	interquartile range
la/mUC	locally advanced/metastatic urothelial carcinoma
LOT	line of therapy
NCCN	National Comprehensive Cancer Network
NCHS	National Center for Health Statistics
NE	not estimable
OP	outpatient
OS	overall survival
PBC	platinum-based chemotherapy
PD-L1	programmed death-ligand 1
PPPM	per patient per month
QCI	Quan–Charlson Comorbidity Index
SD	standard deviation
SDoH	social determinants of health
SES	socioeconomic status
TTNT	time to next treatment
UC	urothelial carcinoma
US	United States